HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
1 published article · Updated continuously
19 trials tracked for Child Development: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 61 citations.
Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
In established trials, home visiting programs showed mixed effects on child development outcomes. The MOM Program home visiting did not significantly improve cognitive or academic scores at age 5 (Woodcock-Johnson Cognitive Ability Test: 89.32 vs 87.62, p=0.39; Broad Reading: 90.92 vs 90.94, p=.99; Broad Math: 94.30 vs 90.80, p=0.16) 6. Similarly, a professional support home visiting model found no significant difference in IQ (WPPSI-III: 86.5 vs 87.4, p=0.59) or internalizing behavior (8% vs 11%, p=0.72), but did show a significant reduction in externalizing behavior problems (3% vs 12%, p<0.01) 7.
Regarding nutritional supplements, LCPUFA oil supplementation did not significantly affect child behavior outcomes, including Pervasive Developmental Disorders Screening Test-II Stage 2 (-1.0 vs -0.2, p=0.67) and BITSEA scores (p=0.22) 4. DHA+AA supplementation significantly altered erythrocyte fatty acid levels (p<0.001) but did not significantly affect infant behavior as measured by the IBQ-R (p=.13) 5.
Azithromycin was studied in a phase 4 trial (N=252) but no specific outcome data were provided for child development 3.
AI synthesis of 11 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.